Market closed
HCW Biologics/$HCWB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About HCW Biologics
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Ticker
$HCWB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
45
Website
HCW Biologics Metrics
BasicAdvanced
$17M
Market cap
-
P/E ratio
-$1.00
EPS
0.84
Beta
-
Dividend rate
Price and volume
Market cap
$17M
Beta
0.84
52-week high
$1.93
52-week low
$0.28
Average daily volume
20M
Financial strength
Current ratio
0.088
Quick ratio
0.069
Long term debt to equity
-64.825
Total debt to equity
-129.687
Interest coverage (TTM)
-93.78%
Management effectiveness
Return on assets (TTM)
-71.95%
Return on equity (TTM)
-537.24%
Valuation
Price to revenue (TTM)
4.12
Price to book
-1.47
Price to tangible book (TTM)
-1.47
Price to free cash flow (TTM)
-0.752
Growth
Revenue change (TTM)
22.27%
Earnings per share change (TTM)
80.90%
3-year revenue growth (CAGR)
-5.17%
3-year earnings per share growth (CAGR)
11.13%
What the Analysts think about HCW Biologics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for HCW Biologics stock.
HCW Biologics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HCW Biologics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HCW Biologics News
AllArticlesVideos
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
GlobeNewsWire·4 weeks ago
Why Is Penny Stock HCW Biologics Surging On Monday?
Benzinga·4 weeks ago
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for HCW Biologics stock?
HCW Biologics (HCWB) has a market cap of $17M as of December 13, 2024.
What is the P/E ratio for HCW Biologics stock?
The price to earnings (P/E) ratio for HCW Biologics (HCWB) stock is 0 as of December 13, 2024.
Does HCW Biologics stock pay dividends?
No, HCW Biologics (HCWB) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next HCW Biologics dividend payment date?
HCW Biologics (HCWB) stock does not pay dividends to its shareholders.
What is the beta indicator for HCW Biologics?
HCW Biologics (HCWB) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.